🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07354646
Recruiting Observational

The Application of T1 Mapping in Real-World

NCT07354646 · tracked via the Priya Life Science China tracker
Sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
Phase
Observational
Started
2020-03-01
Last updated
2026-01-21

Condition(s) studied

Myocardial Infarction (MI)Hypertrophic Cardiomyopathy (HCM)Dilated Cardiomyopathy (DCM)Arrhythmogenic CardiomyopathyMyocarditis

Investigational drug(s) / intervention(s)

Magnetic Resonance Imaging with Contrast

Magnetic Resonance Imaging with Contrast: Participants in this arm undergo a single, standardized cardiac MRI scan with gadolinium-based contrast agent.

Study summary

The goal of this observational study is to create a comprehensive real-world spectrum of T1 mapping measurements across different heart conditions. We aim to establish reference values for how heart tissue characteristics vary in various diseases, which will help doctors better interpret these advanced MRI measurements in clinical practice. The main questions it aims to answer are:

What are the normal T1 mapping values for different heart diseases, and how do they compare to healthy hearts? Can we use the simpler "native T1" measurement (without contrast dye) instead of the more complex "ECV" measurement (which requires contrast dye) for diagnosis?

Patients with various myocardial conditions will undergo CMR T1 mapping scans. We will analyze the MRI images and clinical records to establish disease-specific reference ranges for T1 mapping parameters, and validate the diagnostic accuracy of T1 mapping

Eligibility

Sex
ALL
Min age
Max age
Healthy volunteers
Accepted
Inclusion Criteria: 1. Adult patients (≥18 years) with clinically diagnosed myocardial diseases based on current international guidelines. 2. Specific disease categories include: * Cardiomyopathies (HCM, DCM, RCM, ACM) * Infiltrative disorders (cardiac amyloidosis, Fabry disease) * Inflammatory conditions (acute/chronic myocarditis) * Ischemic heart disease (acute/chronic MI) * Valvular heart disease (aortic stenosis) * Arrhythmic conditions (atrial fibrillation) * Metabolic disorders (iron-overload) * Neoplastic conditions (cardiac tumors) * Congenital heart disease * Post-transplant evaluation 3. All diagnoses must be confirmed using established guideline-based criteria: * Echocardiographic parameters meeting disease-specific cutoffs * Cardiac MRI findings consistent with current consensus criteria * Laboratory biomarkers supporting respective diagnoses * Histopathological confirmation when clinically indicated Exclusion Criteria: * Presence of multiple cardiomyopathy diseases or risk factors simultaneously * Contraindications to CMR examination * Poor image quality precluding accurate T1 mapping analysis * Incomplete clinical data for definitive diagnosis confirmation * Pregnancy or lactation * Inability to provide informed consent

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Fuwai Hospital, Chinese Academy of Medical Sciences Beijing Beijing Municipality Recruiting

More Chinese Academy of Medical Sciences, Fuwai Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07354646 on ClinicalTrials.gov ↗ ← All trials in China